Optimized high-dose amoxicillin–proton-pump inhibitor dual therapies fail to achieve high cure rates in China
| Autor: | Ping Li, Jia-Li Hu, Ran Han, Dian-Chun Fang, Yin-Bin Zhou, Jun Yang |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
Male
Gastroenterology eradication rate 0302 clinical medicine Clarithromycin Medicine biology Middle Aged Anti-Bacterial Agents Treatment Outcome Breath Tests 030220 oncology & carcinogenesis Gastritis Rabeprazole 030211 gastroenterology & hepatology Original Article Drug Therapy Combination Female medicine.drug Adult medicine.medical_specialty China Peptic Ulcer medicine.drug_class Proton-pump inhibitor bismuth-containing quadruple regimen Drug Administration Schedule Helicobacter Infections 03 medical and health sciences Internal medicine Humans lcsh:RC799-869 Adverse effect Helicobacter pylori business.industry Amoxicillin Proton Pump Inhibitors dual therapy biology.organism_classification Surgery Regimen Pharmacodynamics lcsh:Diseases of the digestive system. Gastroenterology business Bismuth |
| Zdroj: | Saudi Journal of Gastroenterology : Official Journal of the Saudi Gastroenterology Association The Saudi Journal of Gastroenterology, Vol 23, Iss 5, Pp 275-280 (2017) |
| ISSN: | 1998-4049 1319-3767 |
| Popis: | Background\Aim: Quadruple daily administration of proton-pump inhibitor (PPI) therapy achieves potent acid inhibition, and combined with amoxicillin, with its pharmacodynamic and pharmacokinetic characteristics, may be efficient for Helicobacter pylori eradication. We compared the efficacy of two optimized high-dose dual therapies with a bismuth-containing quadruple regimen for treating H. pylori infection. Rabeprazole dosages for H. pylori eradication were also evaluated. Patients and Methods: Treatment-naive and H. pylori-positive subjects were recruited and randomly apportioned to three treatment groups: Group A (n = 87), rabeprazole 10 mg plus amoxicillin 750 mg (4 times/day for 14 days); Group B (n = 87), rabeprazole 20 mg plus amoxicillin 750 mg (4 times/day for 14 days); and Group C (n = 89), bismuth-containing quadruple regimen consisting of rabeprazole 20 mg, bismuth 220 mg, amoxicillin 1000 mg, and clarithromycin 500 mg (2 times/day for 14 days). Four weeks after treatment discontinuation, patients were examined for H. pylori infection by 13C-urea breath test. The rates of adverse effects, compliance, and eradication were evaluated. Results: Eradication rates in groups A, B, and C were 78.1, 81.6, and 84.3%, respectively, based on intention-to-treat analysis, or 79.1, 83.5, and 86.2%, according to per-protocol analysis. Rates of adverse events and compliance of the three groups were similar. Conclusion: For treating H. pylori infection, optimized high-dose amoxicillin–PPI dual therapies failed to achieve high cure rates in China and held no advantage over a bismuth-containing quadruple regimen. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|